Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Diagnostics and laboratory products / Molecular and specialised diagnostics

SubmarketREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Molecular and specialised diagnostics

Molecular assays, sequencing-based products and specialty diagnostic systems for targeted disease, oncology and inherited-condition testing, including associated reagents and consumables.

Market size
$14.8B
$14.8B ($11.0B–$20.0B) · 2025 · Bottom-up
Growth
+6.6%
$26.0B by 2032
Attractiveness
75 /100
for B2B sellers
Evidence
Low confidence
3 sources · Bottom-up
Level
Submarket
Segmented by
Customer type
Buyers
Hospital laboratories, specialised diagnostic providers, biotechnology and pharmaceutical companies
Buying centre
Laboratory leadership, pathologists, molecular diagnostics specialists, procurement, regulatory affairs, finance
Maturity
Growth
Structure
Moderately concentrated
Buying triggers
  • New panel and sequencing-based product approvals
  • Oncology and rare-disease testing reimbursement decisions
  • AI-enabled diagnostic device authorisations [2]
  • Targeted M&A and licensing deals [2]
Pains
  • Long assay development and validation cycles
  • Low throughput and high cost per test limiting access
  • Complex sample logistics and cold chain
  • Fragmented interpretation and reporting workflows
Scores (1–5)
Pain intensity4
Purchasing power4
Reachability3
Growth4
Growth drivers
  • Fast adoption of molecular panels in North America [1]
  • Targeted oncology and inherited-condition testing expanding test menus
  • AI-enabled diagnostics investment and M&A resurgence [2]
  • Specialty assay pricing power versus commoditised chemistry [7]
Headwinds
  • High cost per test and reimbursement hurdles for broad panels
  • Regulatory and validation burden lengthening time to market
  • China pricing reform as a structural headwind in Asia-Pacific [7]
Trends
  • Sequencing-based products moving toward mainstream panels [1]
  • Consolidation among large listed diagnostics players [3][4]
  • AI interpretation layers becoming a commercial attachment point [2]

Niches 4

Split by customer type.

Niche

Hospital laboratory routine molecular infectious-disease testing

Molecular assays (respiratory, GI, bloodstream, meningitis panels and single-target PCR) run in hospital and clinical laboratories to support routine inpatient and outpatient diagn

$8.8B
Hospital and clinical laboratories (public and private hospital systems, integrated lab networks)
Low confidenceOpen
Niche

Complex genomic and specialised testing for inherited disease and oncology profiling

Sequencing-based and array/PCR-plus-molecular specialty products used to diagnose inherited and rare conditions and to profile tumour genomics for targeted therapy selection, inclu

$7.3B
Specialised diagnostic providers (reference laboratories, molecular pathology labs) and hospital laboratories operating referral/genomic testing services
Low confidenceOpen
Niche

Rapid and point-of-care molecular testing for acute-care decisions

Compact, cartridge-based molecular systems used at the point of care or near the bedside (emergency departments, urgent care, intensive care, outpatient clinics) to return a syndro

$2.6B
Hospital laboratories and acute-care departments, plus specialised diagnostic providers operating urgent-care and ambulatory sites
Low confidenceOpen

How this was sized

$14.8B ($11.0B–$20.0B) · 2025 · Bottom-up

Bottom-up: molecular diagnostics estimated at ~12% of the USD 118.6bn global diagnostic tests market (2025) [3][4], giving ~USD 14.2bn, plus specialty/oncology and inherited-condition systems not captured in that base, rounded to USD 14.8bn. Cross-check: North America, at 40.0% of clinical diagnostics value [1], is the fastest adopter of molecular panels [1]; Roche Diagnostics grew 2% at constant exchange rates in 2025 [3][4]. Forecast scaled at the 6.60% CAGR [3][4] to ~USD 26bn by 2032. Low confidence: no source publishes a standalone molecular diagnostics revenue pool.

Alongside it in Diagnostics and laboratory products

// Sell into Molecular and specialised diagnostics

AOS finds the biggest accounts in this submarket with a reason to talk now, maps their buying centre and prepares the outreach for your approval.